

PERSONAL INFORMATION **Ekaterini Tiligada**

WORK EXPERIENCE

- February 2018- Present **Professor of Experimental Pharmacology**
National and Kapodistrian University of Athens Medical School (Greece)
Academic (higher education teaching & research)
- June 2008-January 2018 **Associate Professor of Experimental Pharmacology**
National and Kapodistrian University of Athens Medical School (Greece)
Academic (higher education teaching & research)
- March 1999-June 2008 **Assistant Professor of Experimental Pharmacology**
University of Athens Medical School (Greece)
Academic (higher education teaching & research)
- June 1991-March 1999 **Lecturer in Experimental Pharmacology**
University of Athens Medical School (Greece)
Academic (higher education teaching & research)
- October 1986-July 1989 **Demonstrator in Pharmacology**
University of Wales College of Medicine, Cardiff (United Kingdom)

EDUCATION AND TRAINING

- September 1986-August 1989 **Ph.D. in Pharmacology**
University of Wales College of Medicine, Cardiff (United Kingdom)
PhD Research in neuropharmacology (Department of Pharmacology & Therapeutics)
- September 1983-July 1986 **B.Sc. Biochemistry (Honours)**
University of Wales, University College Cardiff (United Kingdom)
Option Medical Biochemistry

ADDITIONAL INFORMATION

- Expertise**
- 1995-to date: IMMUNOPHARMACOLOGY/INFLAMMATION: Investigation and evaluation of the functional/modulatory role of inflammatory mediators, such as histamine, NO & cytokines in hypersensitivity reactions and inflammatory responses under physiological & pathological conditions, including allergic responses, autoimmune diseases and drug allergy. The aim is to determine the involvement of mediators of inflammation in the adaptive and protective mechanisms that underlie the response to various stimuli and to evaluate potential beneficial pharmacological intervention(s), largely focusing on the histamine H3/4 receptor as a novel drug target (preclinical evaluation in in vivo animal models, unicellular eukaryotes, ex vivo human samples and primary cell cultures)
- 1993-to date: CELLULAR STRESS RESPONSE & ageing in eukaryotic cells; signal transduction & environmental influence
- 1990-2005: Investigation of CELL CYCLE CONTROL (pharmacological screening)
- 1986-1990: NEUROPHARMACOLOGY: the neuromodulatory role of peptides in the CNS

ORIGINAL RESEARCH ARTICLES

1. Kakolyri M, Strikou F, Kavallari A, Chliva C, Makris M, Tiligada E (2020) Increased basal blood histamine levels in patients with self-reported hypersensitivity to non-steroidal anti-inflammatory drugs. *Int Arch Allergy Immunol* 181:24-30. DOI: 10.1159/000503968.
2. Tsilochristou O, Kyriakakou M, Manolaraki I, Lakoumentas J, Tiligada E, Maragkoudakis P, Douladiris N, Papadopoulos NG (2019) Detection of local allergic rhinitis in children with chronic, difficult-to-treat, non-allergic rhinitis using multiple nasal provocation tests. *Pediatr Allergy Immunol* 30:296-304. DOI: 10.1111/pai.13021.
3. Papamichael K, Delitheos B, Mourouzis I, Pantos C, Tiligada E (2019) L-Thyroxine induces thermotolerance in yeast. *Cell Stress Chaperones* 24:469-473. DOI: 10.1007/s12192-019-00978-0.
4. Veglia E, Pini A, Moggio A, Grange C, Premoselli F, Miglio G, Tiligada K, Fantozzi R, Chazot PL, Rosa AC (2016) Histamine type 1-receptor activation by low dose of histamine undermines human glomerular slit diaphragm integrity. *Pharmacol Res* 114:27-38. DOI 10.1016/j.phrs.2016.10.011
5. Kakolyri M, Margaritou A, Tiligada E (2016) Dimethyl sulfoxide modifies growth and senescence and induces the non-reversible petite phenotype in yeast. *FEMS Yeast Res* 16(2):fow008. DOI 10.1093/femsyr/fow008
6. Kyriakidis K, Zampeli E, Palaiologou M, Tiniakos D, Tiligada E (2015) Histamine H3 and H4 receptor ligands modify vascular histamine levels in normal and arthritic large blood vessels in vivo. *Inflammation* 38(3):949-958. DOI 10.1007/s10753-014-0057-1
7. Chliva C, Aggelides X, Makris M, Katoulis A, Rigopoulos D, Tiligada E (2015) Comparable profiles of serum histamine and IgG4 levels in allergic beekeepers. *Allergy* 70(4):457-460. DOI 10.1111/all.12568
8. Makris M, Aggelides X, Chliva C, Katoulis A, Papamichael K, Tiligada E (2014) High basal blood histamine levels in a patient with ranitidine-induced anaphylaxis. *J Investig Allergol Clin Immunol* 24(5):361-363.
9. Michelis F, Delitheos A, Tiligada E (2013) Seasonal influence on mitogen and cyclosporin responses of peripheral blood lymphocytes. *Int Immunopharmacol* 16(2):154-159. DOI 10.1016/j.intimp.2013.03.023
10. Pantos SI, Tiligada (2013) Protein backbone structure determination using RDC: An inverse kinematics approach. *Int J Quant Chem* 113(8):10951106. DOI 10.1002/qua.24166
11. Makris M, Koulouris S, Katoulis A, Tyiligada E, Rigopoulos D (2013) Non-immediate, severe hypersensitivity reaction to iopamidol with cross reactivity to different radiocontrast agents. *Allergol Int* 62(1):145-146. DOI 10.2332/allergolint.12-LE-0455
12. Papamichael K, Delitheos B, Tiligada E (2013) A subset of histamine receptor ligands improve thermotolerance of the yeast *Saccharomyces cerevisiae*. *J Appl Microbiol* 114(2):492-501. DOI 10.1111/jam.12055
13. Koti I, Weller K, Makris M, Tiligada E, Psaltopoulou T, Papageorgiou C, Baiardini I, Panagiotakos D, Braido F, Maurer M (2013) Disease activity only moderately correlates with quality of life impairment in patients with chronic spontaneous urticaria. *Dermatology* 226(4):371-379. DOI 10.1159/000351711
14. Bessinis DP, Dalla C, Daifoti ZP, Tiligada E (2012) Histamine involvement in visual development and adaptation. *Invest Ophthalmol Vis Sci* 53(12):7498-7503. DOI 10.1167/iovs.12-10809
15. Michelis FV, Delitheos A, Tiligada E (2011) Molybdate modulates mitogen and cyclosporin responses of human peripheral blood lymphocytes. *J Trace Elements Med Biol* 25(3):138-142. DOI 10.1016/j.jtemb.2011.07.002
16. Papathanassiou M, Giannoulaki V, Zampeli E, Tiligada E (2011) Effect of aminoguanidine on the conjunctival histamine and nitric oxide levels in experimental conjunctivitis *J Ocular Pharmacol Ther* 27(2):137-142. DOI 10.1089/jop.2010.0147
17. Papaioannou G, Michelis F, Papamichael K, Karga H, Tiligada E (2011) Blood lymphocyte blastogenesis in patients with thyroid dysfunction: ex vivo response to mitogen activation and cyclosporin A. *Inflamm Res* 60(3):265-270. DOI 10.1007/s00011-010-0264-7

18. Delitheos B, Papamichael K, Tiligada E (2010) Histamine modulates the cellular stress response in yeast. *Amino Acids* 38(4):12191226. DOI 10.1007/s00726-009-0333-9
19. Persidis S, Moshos M, Katramadou M, Tyiligada K, Carageorgiou H (2010) Histopathologic modifications of rabbit conjunctiva after the administration of latanoprost, travoprost, vimatoprost and combinations with timolol: Preliminary report. *Rev Clin Pharmacol Pharmacokinet Int Ed* 24(2):200-201.
20. Zampeli E, Thurmond RL, Tiligada E (2009) The histamine H4 receptor antagonist JNJ7777120 induces increases in the histamine content of the rat conjunctiva. *Inflamm Res* 58(6):285-291. DOI 10.1007/s00011-009-8245-4
21. Zampeli E, Pitychoutis P, Papadopoulou-Daifoti Z, Tiligada E (2009) Systemic challenge with lipopolysaccharide increases histamine levels in the conjunctiva and cartilage, but not hypothalamus of Sprague Dawley rats. *Inflamm Res* 58(S1):S49-50. DOI 10.1007/s00011-009-2003-5
22. Kyriakidis K, Zampeli E, Tiligada E (2009) Histamine levels in whole peripheral blood from women with ductal breast cancer: A pilot study. *Inflamm Res* 58(S1):S73-74. DOI 10.1007/s00011-009-2014-2
23. Yiannakopoulou ECh, Tiligada E (2009) Protective effect of salicylates against hydrogen peroxide stress in yeast. *J Appl Microbiol* 106(3):903-908. DOI 10.1111/j.1365-2672.2008.04061.x
24. Theodorou MC, Tiligada E, Kyriakidis DA (2009) Extracellular Ca²⁺ transients affect poly-(R)-3-hydroxybutyrate regulation by the AtoS-AtoC system in *E. coli*. *Biochem J* 417(3):667-672. DOI 10.1042/BJ20081169
25. Kyriakidis DA, Theodorou MC, Filippou PS, Kyriakidis KD, Tiligada E (2008) Effect of histamine on the signal transduction of the AtoS-AtoC two component system and involvement in poly-(R)-3-hydroxybutyrate biosynthesis in *Escherichia coli*. *Amino Acids* 35(1):45-52. DOI 10.1007/s00726-007-0635-8
26. Papamichael K, Vovou I, Miligkos V, Stavrinidis E, Delitheos A, Tiligada E (2006) Effect of the hsp90 modulators on the heat shock response in eukaryotic cells. *Folia Microbiol* 51(1):33-37. DOI 10.1007/BF02931447
27. Tiligada E, Papamichael K, Vovou I, Delitheos A (2006) Circumvention of the camptothecin-induced resistance during the adaptive cellular stress response. *Anticancer Res* 26(1):421-425.
28. Kakavas S, Tiligada E (2006) Time course of thyroxine on hypothalamic histamine in the rat. *Inflamm Res* 55(S1):S32-33. DOI 10.1007/s00011-005-0029-x
29. Yiannakopoulou ECh, Tiligada E (2006) Acetaminophen modulates the oxidative stress response in eucaryotic cells. *Rev Clin Pharmacol Pharmacokinet Int Ed* 20(2):125-127.
30. Delitheos BA, Tiligada E (2006) A microscopic approach for recording *S. cerevisiae* cells in the stationary phase. *Rev Clin Pharmacol Pharmacokinet Int Ed* 20(2):144-146.
31. Kakavas S, Tiligada E (2005) Hypothalamic histamine levels in hyperthyroid, arthritic and C48/80-treated rats. *Inflamm Res* 54:S30-31. DOI 10.1007/s00011-004-0413-y
32. Papathanassiou , Giannoulaki V, Tiligada (2004) Leukotriene antagonists attenuate the late phase nitric oxide production during the hypersensitivity response in the conjunctiva. *Inflamm Res* 53(8):373-376. DOI 10.1007/s00011-004-1270-4
33. Vovou I, Delitheos A, Tiligada E (2004) The heat shock response is dependent on the external environment and on rapid ionic balancing by pharmacological agents in *Saccharomyces cerevisiae*. *J Appl Microbiol* 96(6):1271-1277. DOI 10.1111/j.1365-2672.2004.02256.x
34. Tiligada E, Giannoulaki V, Papathanassiou M, Karabela S, Sitaras N, Varonos D (2004) Histamine and fluoxetine: common playground in the rat conjunctiva? *Inflamm Res* 53(S1):S41-42. DOI 10.1007/s00011-003-0319-0
35. Giannoulaki V, Papathanassiou , Sitaras NM, Tiligada (2003) Nadroparine inhibits the hypersensitivity response in the conjunctiva. *Eur J Pharmacol* 481(1):119-124. DOI 10.1016/j.ejphar.2003.08.080
36. Peponis V, Papathanasiou M, Kapranou A, Magou C, Tyiligada A, Melidonis AJ, Drosos T, Sitaras NM (2002) Protective role of oral antioxidant supplementation in ocular surface of diabetic

- patients. *Br J Ophthalmol* 86(12):1369-1373. DOI 10.1136/bjo.86.12.1369
37. Michelis F, Tiligada E, Skaltsa H, Lazari D, Skaltsounis AL, Delitheos A (2002) Effects of the flavonoid pilloin isolated from *Marrubium cylleneum* on mitogen-induced lymphocyte transformation. *Pharmac Biol* 40(4):245-248. DOI 10.1076/phbi.40.4.245.8472
38. Stavrinidis E, Delitheos A, Tiligada E (2002) Induction of morphological alterations by antineoplastic agents in yeast. *Folia Microbiol* 47(2):157-160. DOI 10.1007/BF02817674
39. Tiligada E, Giannoulaki V, Sitaras N, Varonos D (2002) Heparin inhibits C48/80 and fluoxetine effects on conjunctival histamine content in vivo. *Inflamm Res* 51(S1):S7-8. DOI 10.1007/PL00022454
40. Aslanis D, Tiligada E (2001) Effect of fluoxetine on the histamine content in the rat conjunctiva. *J Fr Ophtalmol* 24(2):169-171. DOI JFO-02-2001-24-2-0181-5512-101019-ART8
41. Miligkos V, Tiligada E, Papamichael K, Ypsilantis E, Delitheos A (2000) Anticancer drugs as inducers of thermotolerance in yeast. *Folia Microbiol* 45(4):339-342. DOI 10.1007/BF02817558
42. Skaltsa HD, Lazari DM, Mavromati AS, Tiligada EA, Constantinidis TA (2000) Composition and antimicrobial activity of the essential oil of *Scutellaria albida* ssp. *albida* from Greece. *Planta Med* 66(7):672-674. DOI 10.1055/s-2000-8650
43. Tiligada E, Aslanis D, Delitheos A, Varonos D (2000) Changes in histamine content following pharmacologically-induced mast cell degranulation in the rat conjunctiva. *Pharmacol Res* 41(6):667-670. DOI 10.1006/phrs.1999.0637
44. Varvaresou A, Tsantili-Kakoulidou A, Siatra-Papastaikoudi Th, Tiligada E (2000) Synthesis and biological evaluation of indole containing derivatives of thiosemicarbazide and their cyclic 1,2,4-triazole and 1,3,4-thiadiazole analogs. *Arzneimittel-forschung/Drug Res* 50(1):48-54. DOI 10.1055/s-0031-1300163
45. Tiligada E, Stavrinidis E, Manolis C, Delitheos A (1999) Effects of chromatin function inhibitors on yeast whole cells and spheroplasts. *ATLA Altern Lab Anim* 27(6):951-956.
46. Tiligada E, Miligkos V, Ypsilantis E, Papamichael K, Delitheos A (1999) Molybdate induces thermotolerance in yeast. *Lett Appl Microbiol* 29(2):77-80. DOI 10.1046/j.1365-2672.1999.00581.x
47. Delitheos A, Tiligada E, Yiannitsaros A, Bazos I (1997) Antiphage activity in extracts of plants growing in Greece. *Phytomedicine* 4(2):115-122. DOI 10.1016/S0944-7113(97)80055-4
48. Tsoinis A, Varvaresou A, Calogeropoulou Th, Siatra-Papastaikoudi Th, Tiligada A (1997) Synthesis and antimicrobial evaluation of indole containing derivatives of 1,3,4-thiadiazole, 1,2,4-triazole and their open-chain counterparts. *Arzneimittel-forschung Res* 47(3):307-310.
49. Skaltsa H, Lazari D, Loukis A, Aslanis D, Tiligada E (1997) Chemical and biological studies on the essential oil of *Marrubium cylleneum* Boiss. & Heldr. *Pharmac Pharmacol Lett* 7(4):184-186.
50. Tiligada E, Giannakakou P, Karavokyros I, Delitheos A (1996) Effect of calcium channel blockers on the action of various antitumour agents in the yeast *Saccharomyces cerevisiae*. *J Appl Bacteriol* 81(5):481-485. DOI 10.1111/j.1365-2672.1996.tb03536.x
51. Delitheos A, Karavokyros I, Tiligada E (1995) Response of *Saccharomyces cerevisiae* strains to antineoplastic agents. *J Appl Bacteriol* 79(4):379-383. DOI 10.1111/j.1365-2672.1995.tb03151.x
52. Tiligada E, Delitheos A (1993) Involvement of potassium ions in the action of various antineoplastic drugs on the growth of *Saccharomyces cerevisiae*. *Lett Appl Microbiol* 16(5):251-253. DOI 10.1111/j.1472-765X.1993.tb01411.x
53. Tiligada E, Wilson JF (1989) Glutamergic action on alpha-melanocyte-stimulating hormone release from the rat hypothalamus. *J Neuroendocrinol* 1(6):393-395. DOI 10.1111/j.1365-2826.1989.tb00136.x
54. Tiligada E, Wilson JF (1989) Regulation of -melanocyte-stimulating hormone release from superfused slices of rat hypothalamus by serotonin and the interaction of serotonin with the dopaminergic system inhibiting peptide release. *Brain Res* 503:225-228. DOI 10.1016/0006-8993(89)91668-5
55. Tiligada E, Wilson JF (1989) D2-but not D1-dopamine receptors are involved in the inhibitory control of -melanocyte-stimulating hormone release from the rat hypothalamus. *Exp Brain Res* 74(3):645-648. DOI 10.1007/BF00247368
56. Tiligada E, Wilson JF (1988) Ion and ion-channel involvement in -melanocyte-stimulating

hormone secretion from superfused slices of the rat hypothalamus. *Neurosci Lett* 95(1-3):318-322. DOI 10.1016/0304-3940(88)90678-7

57. Tiligada E, Wilson JF (1988) Dopaminergic inhibition of -melanocyte-stimulating hormone release from superfused slices of the rat hypothalamus. *Brain Res* 457(2):379-382. DOI 10.1016/0006-8993(88)90711-1

58. McPherson M, Tiligada E, Bradbury N, Goodchild MC (1987) Altered calmodulin activity in buccal epithelial cells from cystic fibrosis patients. *Clin Chim Acta* 170(2-3):135-142. DOI 10.1016/0009-8981(87)90121-5

REVIEW ARTICLES

59. Tavares LP, Peh HY, Tan WSD, Pahima H, Maffia P, Tiligada E, Levi-Schaffer F (2020) Granulocyte-targeted therapies for airway diseases. *Pharmacol Res* 157:104881. doi: 10.1016/j.phrs.2020.104881.

60. Tiligada E, Ennis M (2020) Histamine pharmacology: from Sir Henry Dale to the 21st century. *Br J Pharmacol* 177(3):469-489. DOI: 10.1111/bph.14524.

61. Tiligada E, Ishii M, Riccardi C, Spedding M, Simon HU, Teixeira MM, Landys Chovel Cuervo M, Holgate ST, Levi-Schaffer F (2015) The expanding role of immunopharmacology: IUPHAR Review 16. *Br J Pharmacol* 172(17):4217-4227. DOI 10.1111/bph.13219

62. Kyriakidis DA, Theodorou MC, Tiligada E (2012) Histamine in two component system-mediated bacterial signalling. *Front Biosci (Landmark Ed)* 17:1108-1119. DOI 10.2741/3976

63. Tiligada E, Kyriakidis K, Chazot PL, Passani MB (2011) Histamine pharmacology and new CNS drug targets. *CNS Neurosci Ther* 17(6):620628. DOI 10.1111/j.1755-5949.2010.00212.x

64. Tiligada E, Zampeli E, Sander K, Stark H (2009) Histamine H3 and H4 receptors as novel drug targets. *Expert Opin Investig Drugs* 18(10):1519-1531. DOI 10.1517/14728220903188438

65. Kyriakidis DA, Tiligada E (2009) Signal-transduction and adaptive regulation through bacterial two-component systems: The *Escherichia coli* AtoSC paradigm. *Amino Acids* 37(3):443-458. DOI 10.1007/s00726-009-0241-z

66. Zampeli E, Tiligada E (2009) The role of H4 receptor in immune and inflammatory disorders. *Br J Pharmacol* 157(1):24-33. DOI 10.1111/j.1476-5381.2009.00151.x

67. Tiligada E (2006) Chemotherapy: induction of stress responses. *Endocr Relat Cancer* 13:S115-124. DOI 10.1677/erc.1.01272

68. Kakavas S, Zampeli E, Papamichael K, Delitheos B, Tiligada E (2006) The mast cell pathway to inflammation and homeostasis: pharmacological insights. *Anti-Inflamm Anti-Allergy Agents Med Chem* 5(4):323-334. DOI 10.2174/187152306778772793

69. Tiligada E (2006) Nuclear translocation during the cross-talk between cellular stress, cell cycle and anticancer agents. *Curr Med Chem* 13(11):1317-1320. DOI 10.2174/092986706776872952

70. Tiligada E, Miligkos V, Delitheos A (2002) Cross-talk between cellular stress, cell cycle and anticancer agents: mechanistic aspects. *Curr Med Chem - Anticancer Agents* 2:553-566. DOI 10.2174/1568011023353976

71. Tiligada E, Wilson JF (1990) Ionic, neuronal and endocrine influences on the proopiomelanocortin system of the hypothalamus. *Life Sci* 46(2):81-90. DOI 10.1016/0024-3205(90)90040-X

EDITORIALS COMMENTARIES REPORTS

72. Chazot PL, Tiligada E (2020) Challenges in the development and exploitation of new therapeutic options targeting the histaminergic system. *Br J Pharmacol* 177(3):467-468. doi: 10.1111/bph.14947.

73. Kavallari A, Küster T, Papadopoulos E, Hondema LS, Øines Ø, Skov J, Sparagano O, Tiligada E (2018) Avian mite dermatitis: Diagnostic challenges and unmet needs. *Parasite Immunol* 40:e12539. DOI 10.1111/pim.12539.

74. Tiligada E (2016) Editorial to the special issue on the challenge of histamine and histamine receptor pharmacology and therapeutics in the 21st century. *Pharmacol Res* 114:74. DOI 10.1016/j.phrs.2016.10.009

75. Siebenhaar F, Falcone FH, Tiligada E, Hammel I, Maurer M, Sagi-Eisenberg R, Levi-Schaffer F

- (2015) The search for mast cell and basophil models - Are we getting closer to pathophysiological relevance? *Allergy* 70(1):1-5. DOI 10.1111/all.12517
76. Almouzni G, Altucci L, Amati B, Ashley N, Baulcombe D, Beaujean N, Bock C, Bongcam-Rudloff E, Bousquet J, Braun S, De Paillerets Bb, Bussemakers M, Clarke L, Conesa A, Estivill X, Fazeli A, Grgurevi Na, Gut I, Heijmans Bt, Hermouet S, Houwing Duistermaat J, Iacobucci I, Ila J, Kandimalla R, Krauss-Etschmann S, Lasko P, Lehmann S, Lindroth A, Majdi G, Marcotte E, Martinelli G, Martinet N, Meyer E, Miceli C, Mills K, Moreno-Villanueva M, Morvan G, Nickel D, Niesler B, Nowacki M, Nowak J, Ossowski S, Pelizzola M, Pochet R, Poto Nik U, Radwanska M, Raes J, Rattray M, Robinson Md, Roelen B, Sauer S, Schinzer D, Slagboom E, Spector T, Stunnenberg Hg, Tiligada E, Torres-Padilla Me, Tsonaka R, Van Soom A, Vidakovi M, Widschwendter M (2014) Relationship between genome and epigenome - challenges and requirements for future research. *BMC Genomics* 15 (1):487 DOI 10.1186/1471-2164-15-487 (authors in alphabetical order)
77. Tiligada E (2012) Is histamine the missing link in chronic inflammation? *J Leukoc Biol* 92(1):4-6. DOI 10.1189/jlb.0212093
78. Tiligada E (2012) Meeting Report of the Cost Action BM0806 Recent advances in histamine receptor H4R research. *Inflamm Res* 61(S2):42-43. DOI 10.1007/s00011-012-0531-x
79. Tiligada E (2010) Meeting report of the COST action. *Inflamm Res* 59(S4):S308-309. DOI 10.1007/s00011-010-0263-8
80. Chazot PL, Tiligada E (2008) The European Histamine Research Society (EHRS) symposium for EPHAR 2008. *Inflamm Res* 57:S56. DOI 10.1007/s00011-007-0638-7
81. Tiligada E (2006) Editorial: Trends in inflammation - Leads in immunopharmacology. *Anti-Inflamm Anti-Allergy Agents Med Chem* 5(4):287-288. DOI 10.2174/187152306778772810
82. Papadopoulou-Daifoti Z, Tiligada E (2001) Pharmacology of the future - Pharmacogenomics. *Rev Clin Pharmacol Pharmacokinet Int Ed* 15(3):143-146.
83. Tiligada E, Michelis F, Delitheos A (2001) Investigation of the immunomodulatory effects of natural products by an in vitro lymphocyte transformation assay. *Rev Clin Pharmacol Pharmacokinet Intl Ed* 15(3):169-172.
- CHAPTERS IN INTERNATIONAL BOOKS
84. Tiligada E, Gerasimidou K, Levi-Schaffer F (2018) Innovative drugs for allergies. In Riccardi C, Levi-Schaffer F, Tiligada E (Eds). *Immunopharmacology and Inflammation*. Springer International Publishing AG, Chapter 14, pp. 309-321
85. Rigopoulos D, Tiligada E (2017) Stratum corneum lipids and water-holding capacity. In Neelam A. Vashi and Howard I. Maibach (Eds). *Dermatoanthropology of ethnic skin and hair*. Springer International Publishing AG, Chapter 6, pp. 63-74
86. Tiligada E, Ennis M (2017) Preface. In Ekaterini Tiligada and Madeleine Ennis (Eds.) *Histamine receptors as drug targets, Methods in Pharmacology and Toxicology*. New York, USA, Springer Science+Business Media LLC: pp. v-ix
87. Tiligada E, Kakolyri M, Ennis M (2017) Histamine quantification in human blood samples. In Ekaterini Tiligada and Madeleine Ennis (Eds.) *Histamine receptors as drug targets, Methods in Pharmacology and Toxicology*. New York, USA, Springer Science+Business Media LLC, Chapter 17, pp. 489-508
88. Tiligada E (2013) Perspectives in H4R research and therapeutic exploitation. In H. Stark (Ed.) *Histamine H4 receptor: a novel drug target for immunoregulation and inflammation* (Chapter 10, pp. 333-352). London, UK: Versita. ISBN (Online): 9788376560564, DOI (Book): 10.2478/9788376560564
89. Kyriakidis D, Tiligada E (2013) Non receptor-mediated histamine actions. In H. Stark (Ed.) *Histamine H4 receptor: a novel drug target for immunoregulation and inflammation* (Chapter 9, pp. 309-332). London, UK: Versita. ISBN (Online): 9788376560564, DOI 10.2478/9788376560564
90. Papamichael K, Tiligada E (2008) Heat shock proteins in adaptive and protective physiology and pathophysiology of the gastrointestinal mucosa. In E. Morel & C. Vincent (Eds.), *Heat-Shock Proteins: International Research* (Chapter XVI, pp. 299-319). NY: Nova Science Publishers Inc. ISBN: 978-1-60456-641-3

Projects

NATIONAL PROGRAMS

- 2009-2013: The immunopharmacological role of histamine in the inflammatory response, KAPODISTRIAS NKUA, Greece [70/4/5900] (Coordinator E. Tiligada)
- 2008-2009: Inflammatory mediators in the GI tract under pathological conditions, STATE SCHOLARSHIPS FOUNDATION-, Greece [15841/02.12.2008] (Coordinator E. Tiligada)
- 2005-2013: Development of methodology for the determination of cytokines in tissues and biological fluids under physiological and pathological conditions, HELLENIC MINISTRY OF HEALTH, Greece [70/3/8309] (Coordinator E. Tiligada)
- 2005-2007: The immunopharmacological role of histamine in the rat eye under physiological and pathological conditions, KAPODISTRIAS NKUA, Greece [70/4/5900] (Coordinator E. Tiligada)
- 2005-2007: The role of salicylates in preconditioning during oxidative stress, STATE SCHOLARSHIPS FOUNDATION-, Greece [15109/07.10.2005] (Coordinator E. Tiligada)
- 2004-2007: The neuroimmunopharmacological role of histamine in the hypothalamus, Herakleitos HELLENIC MINISTRY OF EDUCATION, Greece [70/3/7208] (Coordinator E. Tiligada)
- 2004: Determination of interleukins in type I hypersensitivity reactions, EMPEIRIKEION FOUNDATION, Greece (Coordinator E. Tiligada)
- 2003: Investigation of the role of nitric oxide (NO) in ocular hypersensitivity reactions, KAPODISTRIAS NKUA [70/4/5900] (Coordinator E. Tiligada)
- 2001: Assay development for nitric oxide (NO) determination in the rat eye, KAPODISTRIAS NKUA [70/4/5900] (Coordinator E. Tiligada)
- 2000: Network of Environmental estrogens and their effects in human health and disease, GENERAL SECRETARIAT OF RESEARCH AND DEVELOPMENT, MINISTRY OF DEVELOPMENT, Greece (Coordinator P. Moutsatsou)
- 1998, 2002-2003: Changes in histamine levels in the rat conjunctiva following administration of various drugs, Development of histamine quantification in the rat brain, FACULTY OF MEDICINE NKUA, Greece (Coordinator E. Tiligada)
- 1999: Effect of immunoregulatory and antineoplastic agents in lymphocyte blastogenesis, RESEARCH COMMITTEE, NKUA, Greece [70/4/2590] (Coordinators . Delitheos/E. Tiligada)
- 1999: Allergic reactions in the rat eye, CENTRAL HEALTH COUNCIL (KESY) Hellenic Ministry of Health, Greece [70/3/4588] (Coordinator E. Tiligada)
- 1999, 2001, 2004-2005: Pharmacologically active agents in the stress response in *S. cerevisiae*, FACULTY OF MEDICINE NKUA, Greece (Coordinator E. Tiligada)
- 1997-1998: Development of methodology for the investigation of ocular allergic reactions in the rat, RESEARCH COMMITTEE, NKUA, Greece [70/4/3571] (Coordinator E. Tiligada)
- 1996: New indole-containing compounds with antimicrobial, antifungal and CNS effects, PENED General Secretary of Research & Technology, Greece [70/3/2742] (Coordinator Th. Siatra-Papastaikoudi)
- 1994: Effects of calcium channel blockers in the action of antineoplastic agents, CENTRAL HEALTH COUNCIL (KESY), Hellenic Ministry of Health, Greece [70/3/1667] (Coordinator E. Tiligada)
- 1994: Ion channel involvement in the action of antineoplastic agents, RESEARCH COMMITTEE, NKUA, Greece [70/4/1738] (Coordinator E. Tiligada)
- 1992-1997: Effect of antineoplastic agents on the morphology and cell cycle of *S. cerevisiae*, Effect of ion channel functional alterations in the action of antineoplastic agents, FACULTY OF MEDICINE NKUA, Greece (Coordinator E. Tiligada)

INTERNATIONAL PROGRAMS

- 2014-2008: COST Action FA1404: Improving current understanding and research for sustainable control of the poultry red mite *Dermanyssus gallinae* (COREMI), EUROPEAN COOPERATION IN SCIENCE AND TECHNOLOGY, EU Framework Programme Horizon 2020 (Coordinator O. Sparagano, UK)
- 2012-2015: Implementation of the basophil histamine release (HR) technique [non-profit external investigation] (Coordinators PS Skov, Denmark & E. Tiligada, Greece)
- 2011-2015: COST BM1007: Mast Cells and basophils - Targets for innovative therapies,

COPERATION IN SCIENCE AND TECHNOLOGY, EU RTD Framework Programme FP7
(Coordinator M. Maurer, Germany)

2010-2015: Pharmacological evaluation of novel H4R ligands [non-profit investigation]
(Coordinators H. Stark, Germany & E. Tiligada, Greece)

2009-2013: Effects of the histamine H3 receptor on the histamine content of peripheral and central tissues in a rat model of experimental arthritis [non-profit external (non-clinical) investigation]
GLAXOSMITHKLINE R&D LTD, UK (Coordinators AD Medhurst, UK & E. Tiligada, Greece)

2008-2013: COST BM0806: Recent advances in histamine receptor H4R research, EUROPEAN
COPERATION IN SCIENCE AND TECHNOLOGY, EU RTD Framework Programme FP7
(Coordinator E. Tiligada, Greece)

2004-2012: Pharmacological investigation of the H4 receptor antagonist JNJ7777120 JOHNSON &
JOHNSON PHARMACEUTICAL, R&D, San Diego, CA USA (Coordinators RL Thurmond USA & E.
Tiligada, Greece)

1988: CNRS650/INSERM, Université de Rouen (Coordinators H. Voudry & S. Jegou, France)

1986-1989 Control of alpha-MSH release from the arcuate nucleus of the rat, UNIVERSITY OF
WALES COLLEGE OF MEDICINE, CARDIFF, UK (Coordinator JF Wilson, UK)

Memberships

MEMBERSHIP IN SCIENTIFIC SOCIETIES

2012-to date: International Union of Pharmacology (IUPHAR) Immunopharmacology Section
[2012-2018: Treasurer; 2018-to date: VICE CHAIR]

2001-to date: European Histamine Research Society [EHRS, 2006-2009 & 2014-2018: Council
Officer; 2018-to date PRESIDENT]

1999-to date: Greek Pharmacological Society

1992-to date: British Pharmacological Society (BPS)

1991-to date: Hellenic Society of Biochemistry & Molecular Biology (HSBMB)

EDITORIAL BOARDS/COMMITTEES

2015-to date: Editor, British Journal of Pharmacology, ISSN: 1476-5381, Wiley [IF2017 6.81]

2015-to date: Editor, Biomedical Data Journal (BMDJ) [open access, ISSN 2367-5322, e-ISSN
2367-6477]

1995-to date: ad hoc Reviewer (various international peer-review scientific journals)

2016-to date: NC-IUPHAR Corresponding Member

2016-to date: Chair of the Research Protocol Evaluation Committee, Animal house facilities EL 25
BIO 10, Laboratory of Pharmacology, Medical School, NKUA, Greece

Other Relevant Information

TEACHING EXPERIENCE

Part time (1986-1991) and full time (1991-to date) teaching engagements in the field of
Pharmacology comprising (a) teaching of Higher Education undergraduate and postgraduate
Medical (mostly), Dental, Pharmacy, Nursing Studies and Biology students, (b) lectures and
seminars in medical residency programs, (c) lectures in 3 European Training Schools, (d)
supervision of 7 MSc students, 17 PhD candidates and 2 postdoctoral fellows, (e) training of a
number of young scientists and early career researchers from Greece and abroad at undergraduate
and postgraduate level.

2016-to date: Course coordinator, "Pharmacology I" & "Pharmacology II" (5th & 6th semesters) for
Dental students, Department of Dentistry, NKUA, Athens, Greece.

2012-2017: Pharmacology course coordinator, Postgraduate Studies Programme "Applications of
Biology in Medicine", Faculties of Biology & Medicine, NKUA, Athens, Greece, Coordinator:
Professor . Papisideri.

2003-2005: Course coordinator "Elements of Molecular Pharmacology", Laboratory of
Pharmacology, Faculty of Medicine, NKUA, Athens, Greece

ORGANIZATION, MANAGEMENT AND ADMINISTRATIVE EXPERIENCE

The organizational and administrative engagements include (a) organization and management of
academic research groups, (b) coordination and/or participation in National and European
committees, (c) board officer of international scientific societies, (d) organization of scientific

conferences, coordination of meeting sessions, invited lectures, (f) editorial board member of scientific journals and (g) participation in elective bodies for the recruitment and promotion of faculty members of the Faculty of Medicine of the NKUA.

2018-to date: President, EUROPEAN HISTAMINE RESEARCH SOCIETY (EHRS) [elected at the 47th meeting, Dublin, Ireland]

2018-to date: Vice Chair, IMMUNOPHARMACOLOGY SECTION, INTERNATIONAL UNION OF BASIC & CLINICAL PHARMACOLOGY (IUPHAR) [elected at the WCP2018, Kyoto, Japan]

2016-to date: NC-IUPHAR Corresponding Member, IUPHAR/BPS GUIDE TO PHARMACOLOGY

2016-to date: Chair, RESEARCH PROTOCOL EVALUATION COMMITTEE, Animal house facilities EL 25 BIO 10, Laboratory of Pharmacology, Medical School, NKUA, Greece

2015-2018: Council Officer, EHRS [elected at the 44th meeting, Malaga, Spain]

2014-2018: Management Committee member and Working Group Leader (ONE HEALTH) COST Action FA1404 COREMI, EU Horizon 2020

2014-to date: Observer in the Rheumatology-Immunology Working Party (RIWP), EUROPEAN MEDICINES AGENCY (EMA), London, UK

2014-2018: Treasurer, IUPHAR IMMUNOPHARMACOLOGY SECTION [elected at WCP2014, Cape Town, South Africa]

2011-2015: Management Committee member, COST Action BM1007, EU FP7

2008-2013: Chair, COST Action BM0806 EU FP7

2007-2009: School Ambassador, «SET-Routes» (EMBL, EMBO, CERN) EU FP6

2006-2009: Council Officer, EHRS [elected at the 35th meeting, Delphi, Greece]

SCIENTIFIC MEETINGS

- Chairperson or member of the Organizing Committee of 11 international conferences
- Member of the Scientific Committee and/or Abstract & Award Committees in 28 conferences (15 Greek, 13 international)
- Session Chair in 26 conferences (5 Greek and 21 international)
- Participation in 7 European discussion panels
- Invited lectures in 72 conferences and meetings (34 Greek, 22 international, 6 public, 10 other)

BOOK EDITOR

2018: Immunopharmacology and Inflammation, Carlo Riccardi, Francesca Levi-Schaffer and Ekaterini Tiligada (Eds.), Springer International Publishing AG, part of Springer Nature, Germany: Springer International Publishing [eBook ISBN: 978-3-319-77658-3; Hardcover ISBN: 978-3-319-77657-6; DOI 10.1007/978-3-319-77658-3]

2017: Histamine Receptors as Drug Targets, Ekaterini Tiligada and Madeleine Ennis (Eds.), Methods in Pharmacology and Toxicology, Springer Science+Business Media LLC, part of Springer Nature, NY, USA: Humana Press [eBook ISBN: 978-1-4939-6843-5; Hardcover ISBN: 978-1-4939-6841-1; Softcover ISBN: 978-1-4939-8315-5; DOI 10.1007/978-1-4939-6843-5]

GUEST EDITOR

2018: New uses for 21st century antihistamines, Theme Issue Edited by Paul Chazot and Ekaterini Tiligada, British Journal of Pharmacology, Wiley [IF2017 6.81]

2016: The challenge of histamine and histamine receptor pharmacology and therapeutics in the 21st century, Virtual Special Issue Edited by Ekaterini Tiligada, Pharmacological Research, Elsevier B.V. [IF2017 4.897]

2011: Histamine revisited: the H4 receptor in health and disease Special Issue (Managing Editor: Ekaterini Tiligada) Frontiers in Bioscience, Irvine, CA, USA [IF2017 2.349]

2006: Hot Topic: Trends in Inflammation Leads in Immunopharmacology, Theme Issue, (Guest Editor: Ekaterini Tiligada), Anti-inflammatory & Anti-Ilergy Agents in Medicinal Chemistry, Bentham Science Publishers [DOI 10.2174/187152306778772810]

EVALUATOR/RESEARCH PROGRAMMES

GREEK PROGRAMMES

2019: Expert Evaluator for the State Scholarship Foundation-IKY; Supporting Postdoctoral Researchers - B Cycle

2016: Rapporteur, Research Program ARISTEIA II, General Secretariat for Research & Technology, Greece

2013: Greek-German Collaboration, General Secretariat for Research & Technology, Greece

2011: Evaluation of candidates for MSc studies abroad (Pharmacology), State Scholarship Foundation-IKY

2010: Greek-Hungarian Collaboration, Biosciences domain, General Secretariat for Research & Technology, Greece

2008: Programme for postdoctoral research in Greece, State Scholarship Foundation-IKY,

2007: Member of the Evaluators Board Incentives for private investments for economic development and regional convergence, General Secretariat for Research and Technology, Greece

2004: P International cooperation in industrial research and development activities in a pre-competitive phase 2003, General Secretariat for Research and Technology, Greece

EUROPEAN PROGRAMMES

2017, 2019: External Expert, Open Call, COST, Brussels, Belgium

2016-2017: Expert Evaluator, European Commission Health Research call topic New Therapies for Rare Diseases SC1-PM-08-2017, Brussels, Belgium

2015-to date: Rapporteur, COST Biomedicine & Molecular Biosciences (BMBS) Domain, Brussels, Belgium

2014-to date: Expert Evaluator, Horizon 2020 Marie Skodowska-Curie fellowships (H2020-MSCA-IF), Brussels, Belgium

2014-2015: Expert Evaluator, Horizon 2020 Personalising health and care (H2020-PHC14-2015: New therapies for rare diseases), Brussels, Belgium

2012-to date: Expert reviewer, National Science Centre, Poland

2010-2013: Evaluator, FP7 Marie Curie Career Integration Grants (FP7-PEOPLE-CIG) & Marie Curie Individual fellowships (FP7-PEOPLE-IXF), Brussels, Belgium

2010: External Expert, COST Biomedicine & Molecular Biosciences (BMBS) Domain, Brussels, Belgium

2007: External Evaluator, Sheffield Hospitals Charitable Trust Medical Research Committee, UK